Effect of Acoltremon Ophthalmic Solution 0.003% on Signs and Symptoms of Ocular Surface Disease in Stage I Neurotrophic Keratopathy Patients With Tear Deficiency
Purpose
STUDY OBJECTIVE To assess if acoltremon 0.003% improves tear production in patients with Stage 1 Neurotrophic Keratopathy.
Conditions
- Ocular Surface Disease
- Neurotrophic Keratopathy Stage 1
Eligibility
- Eligible Ages
- Over 18 Years
- Eligible Sex
- All
- Accepts Healthy Volunteers
- No
Inclusion Criteria
- Neurotrophic Keratopathy stage 1 diagnosis based on the following: Presence of 3+ fluorescein staining in central cornea and decreased corneal sensation (Cochet-Bonnet less than 4cm in the central cornea) - Baseline unanesthetized Schirmer's test ≤ 10 mm - Females of childbearing potential must have a negative pregnancy test. - Best corrected distance visual acuity (BCDVA), using corrective lenses, if necessary, in the study eye of at least +1.0 Log MAR (Snellen <20/200).
Exclusion Criteria
- Evidence of any active ocular infection or any intraocular inflammation. - Evidence of any persistent epithelial defect/ulcer or any corneal scar/corneal edema. - Presence of any other ocular conditions that require topical medications during the treatment phase. - History of severe systemic allergies or severe ocular allergies. - Inability to suspend topical medications 8 days prior to the starting date and artificial tears 2 hours prior to the first study visit and remain off for the duration of the study. - History of any ocular surgery within three months before study visit 1. - Ocular surgery expected during the duration of the study. - Use of refractive/therapeutic contact lenses during the study period. - Female subjects who are pregnant/have a positive pregnancy test result or are breastfeeding or intend to become pregnant during the study treatment period. - Drug addiction/alcohol abuse. - Participation in another clinical trial concurrently
Study Design
- Phase
- Phase 4
- Study Type
- Interventional
- Allocation
- N/A
- Intervention Model
- Single Group Assignment
- Intervention Model Description
- This is a single arm trial where all patients receive the same medication in one eye. This study drug is already FDA approved and this is to get further detail of performance of the medication.
- Primary Purpose
- Treatment
- Masking
- None (Open Label)
Arm Groups
| Arm | Description | Assigned Intervention |
|---|---|---|
|
Other Acoltremon 0.003% Ophthalmic Solution |
Open Label treatment of Acoltremon |
|
Recruiting Locations
University of South Florida/Ophthalmology
Tampa, Florida 33612
Tampa, Florida 33612
More Details
- Status
- Recruiting
- Sponsor
- University of South Florida
Detailed Description
This study is designed to provide clinical data on how acoltremon ophthalmic solution 0.003% affects tear production in subjects with stage I neurotrophic keratopathy (NK). The study drug, Acoltremon, is formulated to help increase tear production. Since the tissue breakdown of the cornea is causing NK, it is thought that this study treatment may help participants with this disease by enhancing wound healing, repair and regeneration through improving nerve function of the cornea. Participants will be followed for 8 weeks, evaluating unanesthetized Schirmer test score between 3 minutes post-drop week 8 compared to pre-drop at baseline (day 1), their mean change in Best Corrected distance visual acuity (ETDRS standards) from day 1 to week 8, and change in central corneal staining from baseline to week 8.